Cytotoxic and anti-proliferative effects of high-energy pulsed ultrasound (HEPUS) on human squamous cell carcinoma cells as compared to connective tissue fibroblasts

The cytotoxic and anti-proliferative effects of high-energy pulsed ultrasound (HEPUS) on human squamous cell carcinoma cells cloned from the hypopharynx (FaDu) and benign connective tissue cells (fibroblasts) were investigated in vitro. Sonication was carried out using an experimental piezoelectric, self-focusing burst-signal transducer. To increase the induction of cavitation, the transducer used was specifically designed to produce multiple oscillations with a high negative pressure amplitude. In both cell lines tested, the application of 100, 800 and 2000 pulses resulted in a high reduction of vital cells. After 2000 pulses, 4.0 ± 1.1% of the fibroblasts but only 2.0 ± 0.4% of the FaDu cells survived HEPUS exposure. A postexposure inhibiting effect of HEPUS for 10 days on the proliferation of surviving cells was noted for the FaDu cells exposed to 2000 pulses, but not as much for the fibroblasts. These findings support the hypothesis that human squamous cell carcinoma cells of the hypopharynx might be more sensitive to HEPUS than fibroblasts and that total tumor cell ablation might be possible in vitro given a sufficient number of HEPUS pulses. Received: 18 November 1997 / Accepted: 21 April 1998     

10%盐水冰袋的研制及临床应用

目的　探讨有效实用的临床物理降温方法。方法　选内、外科发热病人及五官科术后病人 10 0例随机分为对照组和观察组各 5 0例 ,对照组采用传统的冰块冰袋 ,观察组用自行研制的 10 %盐水冰袋 (冰霜状 )进行物理降温。结果　 10 %盐水冰袋低温持续时间长 ,冰袋松软 ,接触体表充分 ,易于固定 ,病人自觉舒适 ,降温、止血、止痛效果明显优于传统的清水冰袋 (P <0 0 5 )。结论　 10 %盐水冰袋制作简单、操作方便 ,在临床、社区、家庭护理中可广泛推广使用。     

Paget''s disease of the vulva: clinicopathologic study of type 1 cases treated at a single institution

The aim of this study was to evaluate clinicopathologic characteristics of primary cutaneous Paget's disease of the vulva. Between 1986 and 2005, 22 patients with primary cutaneous Paget's disease of the vulva (type 1) were treated at Tohoku University Hospital. Medical records were reviewed for pathologic diagnosis, patient age, associated neoplasms, type(s) of eczema, symptom duration, treatment, surgical procedures, recurrence, and length of follow-up. Patient age ranged from 51 to 85 years (median 71.5 years). Median duration of symptoms was 24 months (range 2-60 months). Type 1a (intraepithelial) Paget's disease accounted for 18 patients, with 3 type 1b (invasive) cases and 1 type 1c (intraepithelial disease with underlying adenocarcinoma) case. Mean length of follow-up was 53.7 months, and median follow-up was 49 months (range 6-199 months). Only two patients had an associated internal malignancy: T-cell leukemia and breast cancer. Mapping biopsy was performed in 14 of the 18 type 1a cases. All patients were free of disease at the surgical margins and are alive without recurrence. The four patients with type 1b or 1c disease had lymph node metastases. Two has died of disease, and two are alive with no recurrence. The rate of secondary malignancy seems to be low in primary cutaneous Paget's disease of the vulva. Mapping biopsy with careful examination of characteristic skin surface may be useful for surgery of type 1a cases. Inguinal lymphadenectomy is recommended in cases with question of invasion or known underlying adenocarcinoma.     

Supravital staining: It's role in detecting early malignancies

The efficacy of supravital staining in the detection of malignancies in oro and oropharyngeal lesions and its role in the detection of malignant changes in premalignant lesions were studied. This prospective study comprises 90 cases of clinically suspicious lesions and it was done over a period of 3 years. Most of the patients had multiple risk factors for the development of malignancy. All underwent staining with a modified solution of 1% toluidine blue (TB). In our study the overall sensitivity was 97.29% and the specificity was 62.5%.     

强骨胶囊治疗原发性骨质疏松症(骨量减少)的临床研究

目的探讨强骨胶囊防治原发性骨质疏松症(骨量减少)的作用及其机制.方法观察骨量减少(肾阳虚证)患者161例,121例采用随机分组、双盲双模拟对照的方法,其中治疗组61例、骨松宝颗粒对照组60例,其余40例为强骨胶囊开放治疗组.观察中医证候疗效及骨痛、骨密度改变情况.结果强骨胶囊治疗组中医证候总有效率为95.08%,愈显率为60.66%;强骨胶囊开放治疗组分别为92.50%、52.50%;骨松宝颗粒对照组分别为83.33%、31.67%.治疗组中医证候疗效明显优于对照组(P＜0.01).强骨胶囊治疗组骨痛的总有效率为91.08%,愈显率为70.49%;强骨胶囊开放治疗组分别为92.50%、72.50%;骨松宝颗粒对照组分别为81.67%、48.33%;治疗组对骨痛的疗效明显优于对照组(P＜0.01).经过治疗前后双能X线骨密度测定,治疗后治疗组腰椎2-4骨密度平均上升0.02%,股骨粗隆骨密度平均上升5.58%,股骨颈骨密度平均下降0.37%;开放治疗组上述三项分别为上升0.80%、上升3.21%、下降1.36%;对照组分别为下降0.86%、上升0.84%、上升0.40%.结论强骨胶囊治疗原发性骨质疏松症骨量减少疗效确切.     

氢化可的松抑制Jurkat细胞的调节性体积减小

目的 :研究氢化可的松对Jurkat细胞调节性体积减小 (regulatoryvolumedecrease ,RVD)的影响及可能的机制。方法 :通过MoticImagesAdvanced 3.1软件系统实时监测细胞体积的变化 ,并通过3 H掺入实验观察Jurkat细胞增殖。结果 :氢化可的松对Jur kat细胞RVD具有剂量依赖性的抑制作用 ,在 10 -4和 10 -3 mol·L-1时可以明显抑制Jurkat细胞的RVD ,而在 10 -9、10 -7和 10 -5mol·L-1时对Jurkat细胞的RVD没有明显影响。钾通道阻断剂奎宁 (quinine)亦可以抑制Jurkat细胞的RVD。氢化可的松和奎宁在10 -3 mol·L-1均可明显抑制Jurkat的增殖 (包括自然增殖和ConA诱导增殖 )。结论 :氢化可的松对Jur kat细胞RVD的抑制可能是通过钾通道起作用     

Primary Cardiac Lymphoma: Echocardiography and F‐18‐Fluorodeoxyglucose Positron Emission Tomography in Selection of a Biopsy Site

A 63‐year‐old man was referred to our hospital because of a cardiac tumor. Transthoracic echocardiography revealed a rough, mobile tumor in the dilated right atrium, and transesophageal echocardiography showed that the tumor consisted of small, botryoidal masses. Catheter‐based biopsy carried a high risk of embolism. Therefore, we used F‐18‐fluorodeoxyglucose positron emission tomography (FDG‐PET), which revealed an abnormal accumulation in the right cervical lymph nodes, as well as in the heart. We safely performed biopsy of the lymph nodes and diagnosed the patient with primary cardiac lymphoma. We concluded that echocardiography and FDG‐PET are useful for selecting an appropriate biopsy site in primary cardiac lymphoma.     

Phase I Trial of Selective Internal Radiation Therapy for Chemorefractory Colorectal Cancer Liver Metastases Progressing After Hepatic Arterial Pump and Systemic Chemotherapy

IntroductionThis prospective study assessed the safety and outcomes of selective internal radiation therapy (SIRT) using yttrium-90 (⁹⁰Y) resin microspheres as a salvage therapy for liver-predominant metastases of colorectal cancer in patients with documented progression after hepatic arterial chemotherapy (HAC) and systemic chemotherapy.Patients and MethodsWe recruited 19 patients who had received a mean of 2.9 prior lines of chemotherapy and ≥ 1 line of HAC. Dose-limiting toxicities (grade 3 or higher) were catalogued using Common Terminology Criteria for Adverse Events version 3.0. At 4 to 8 weeks and 3 to 4 months post SIRT, responses were assessed by carcinoembryonic antigen (CEA), and quantitative imaging using Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST). Liver progression-free survival (LPFS), progression-free survival (PFS), and overall survival (OS) were calculated using Kaplan-Meier methodology.ResultsMedian follow-up was 31.2 months after SIRT. Within 6 weeks of SIRT, 3 patients (15.8%) experienced grade 3 toxicity. There was no incidence of radiation-induced liver disease. Responses by RECIST, PERCIST, and CEA were, respectively, 0%, 20%, and 32% at 4 to 8 weeks and 5%, 33%, and 21% at 3 to 4 months post SIRT; 53% of patients had stable disease (by RECIST) at 3 to 4 months. Of 19 patients, 4 (21.1%) had liver ablation, 9 (47%) received additional HAC, and 17 (89%) received systemic chemotherapy after SIRT. Median LPFS, PFS, and OS after SIRT were 5.2 months, 2.0 months, and 14.9 months, respectively.ConclusionSIRT was well tolerated and did not prohibit subsequent treatment, resulting in a median OS of 14.9 months in this heavily pretreated population.